High-level expression of AmpC b-lactamase genes is associated with increased resistance to b-lactam antibiotics. bla CMY-2 is the most prevalent plasmid-encoded AmpC gene found in Escherichia coli worldwide, and the gene is often found on plasmids of the IncI1 replicon type. Replication of IncI1 plasmids is controlled by antisense RNA transcribed from the gene inc, and nucleotide changes in the hairpin loop region of inc have been associated with increased plasmid copy number of IncI1 mini-plasmid constructs. The objective of this study was to determine the mechanism(s) responsible for increased bla CMY-2 expression in three piperacillin/tazobactam-selected E. coli mutant strains with bla CMY-2 encoded on a 100 kb IncI1 plasmid.
Introduction
bla CMY-2 is the most frequently encountered plasmid-encoded AmpC b-lactamase gene found in Escherichia coli worldwide. 1 It is derived from the chromosomal ampC gene of Citrobacter freundii, 2 and is typically encoded on plasmids of the IncA/C and IncI1 replicon types. 3, 4 Production of CMY-2 by E. coli is associated with resistance to third-generation cephalosporins and most b-lactam/b-lactamase-inhibitor combinations, including amoxicillin/clavulanic acid and ampicillin/sulbactam. 1,2 E. coli encoding CMY-2 are usually susceptible to carbapenems, cefepime and piperacillin/tazobactam, but resistance to these drugs has been reported in strains with compounding porin deficiencies. 5, 6 Piperacillin/tazobactam is a widely used drug that is recommended for empirical therapy of complicated intra-abdominal infections, 7 healthcare-associated pneumonia 8 and neutropenic fever. 9 However, piperacillin/tazobactam treatment has also been associated with the recovery of piperacillin/tazobactamresistant E. coli from patients. 10, 11 In one cohort study, a 12% increase in the isolation of resistant isolates was seen at the completion of therapy. The contributing mechanisms of resistance in these studies were not fully investigated, and it is unknown whether any of the strains possessed bla CMY-2 . In addition, our laboratory has observed the emergence of piperacillin/tazobactam-resistant mutants from E. coli strains encoding bla CMY-2 following in vitro exposure to piperacillin/ tazobactam.
Past studies of IncI1 plasmid replication models have found that copy number is controlled in part by an approximately 70 nucleotide antisense RNA encoded by the gene inc. The Inc antisense RNA interferes with translation of the plasmid replication initiation protein RepZ by binding to the 5 ′ untranslated region (UTR) of the repZ transcript. 12, 13 A key factor of the interference is the initial binding of the Inc stem loop with its complementary mRNA stem loop (SL1) in the repZ transcript. 14 -16 The result of the joining of the two molecules is referred to as the 'kissing complex'. 17 Single nucleotide changes within the loop region of inc can affect the loop shapes of Inc and SL1 and hinder their ability to form the kissing complex. 18 The inability of Inc to prevent repZ translation leads to increased IncI1 plasmid replication frequency and increased plasmid copy number. 15, 19 Increased plasmid copy number is a mechanism by which E. coli can increase the level of a plasmid-encoded b-lactamase, leading to reduced susceptibility to b-lactam antibiotics. 20 However, gene copy number is rarely evaluated in clinical isolates. 21 In addition, inc mutations, such as those examined in IncI1 mini-plasmid models, and copy-number increases have not been explored in larger clinical IncI1 plasmids of 50-100 kb. The purpose of this study was to examine three in vitro piperacillin/tazobactam-selected mutants that were obtained from an E. coli isolate that had bla CMY-2 encoded on a 100 kb IncI1 plasmid. The data presented in this report showed all three mutants had increased bla CMY-2 expression and that this directly correlated with an increase in the copy number of the IncI1 plasmid. Two strains had point mutations in the stem loop region of inc, demonstrating that such mutations can be associated with increased copy number of a 100 kb IncI1 plasmid in E. coli.
Materials and methods
Strain characterization and antimicrobial susceptibility testing E. coli strain CUMC-50 was isolated from the urine of a paediatric outpatient in 2003. PCR testing 22 -24 showed that the strain possessed bla CMY-2 , but did not encode genes for CTX-M, SHV or TEM extendedspectrum b-lactamases. MICs of piperacillin/tazobactam, aztreonam, ceftazidime, cefepime, imipenem and meropenem were determined for all strains by agar dilution. MICs of ertapenem were determined by Etest w (AB BioDisk, Solna, Sweden). Susceptibility testing was performed and interpreted using CLSI criteria. 25 
Piperacillin/tazobactam mutant selection
Inocula of 10 7 to 10 9 cfu of strain CUMC-50 from log-phase MuellerHinton broth (MHB) culture were suspended in saline and added to molten Mueller-Hinton agar containing piperacillin at concentrations of 8, 16 or 32 mg/L with 4 mg/L tazobactam. Strains growing in the agar that demonstrated at least a 16 mg/L piperacillin/tazobactam MIC (≥4-fold increase compared with the parent) were considered mutants. Strains CUMC-50M2 and CUMC-50M8 were selected using this method. An additional strain, CUMC-50M, was selected from within the elliptical inhibition zone of a piperacillin/tazobactam Etest w assay performed on CUMC-50.
DNA sequencing and transcription start site mapping
For all strains, the DNA sequences of inc, repZ and bla CMY-2 (and upstream regions) were obtained from two independent PCR amplicons generated using primers listed in Table S1 (available as Supplementary data at JAC Online). Transcription start sites were mapped for strains CUMC-50 and CUMC-50M using an Invitrogen 5 ′ RACE Kit (Invitrogen, Carlsbad, CA, USA).
RNA expression assays
Real-time RT-PCR was performed to measure mRNA expression levels of bla CMY-2 , repZ and the chromosomal ampC genes. RNA for each strain was isolated from 3 mL of log-phase MHB culture using TRIzol Max w (Invitrogen) as previously described. 26 Real-time RT-PCRs were performed using Quantitect w SYBR w Green RT-PCR Mastermix and Reverse Transcriptase Mix (QIAGEN, Hilden, Germany) with 250 ng of total RNA and 25 pmol of primer in a total volume of 50 mL. The primer pairs are listed in Table S1 . Reactions were performed using an ABI Prism w 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Relative transcript levels were calculated using the 2 2DDCT method 27 with strain CUMC-50 used as the calibrator. Levels of 23S rRNA transcription were used as internal controls to normalize the data. At least three independent RNA samples isolated from three separate cultures were used to determine average transcript levels for each strain. Only cycle threshold measurements that had a collective coefficient of variation value ,10% were used in the calculations.
Gene copy-number and plasmid copy-number evaluation
The relative copy number of bla CMY-2 and the IncI1 replicon region were determined by real-time PCR assays using primers listed in Table S1 . DNA templates were prepared from 3 mL of log-phase MHB culture using a QIAGEN DNeasy w Blood and Tissue Kit with RNase treatment, according to the manufacturer's instructions. Real-time PCRs were performed and analysed as described for RNA expression, with the single-copy chromosomal gene ampD used to normalize the data.
PFGE and restriction fragment studies
PFGE was performed using the CDC PulseNet protocol. 28 Each agarose plug contained cells from 4 mL of log-phase culture. Plugs were digested with XbaI endonuclease (New England Biolabs, Ipswich, MA, USA) for 12 h and DNA fragments were separated by PFGE using a Bio-Rad GenePath w System (Bio-Rad, Hercules, CA, USA). Total genomic DNA suspended in agarose plugs (prepared by the methods used for PFGE) was also digested with EcoRI (New England Biolabs) for 12 h and separated by unidirectional electrophoresis.
Plasmid isolation and Southern hybridization
Plasmids were isolated from 5 mL of log-phase MHB culture using methods described by Sinnett and Montpetit 29 and treated with PlasmidSafe DNase (EPICENTRE Biotechnologies, Madison, WI, USA) for 1 h. Plasmid DNA was separated by agarose gel electrophoresis and visualized with 0.5× SYBR w Gold Nucleic Acid Gel Stain (Invitrogen). Southern blot analysis was performed on plasmid DNA and restricted genomic DNA using methods described by Sambrook and Russell. 30 A 172 bp digoxigenin-labelled bla CMY-2 -specific probe was synthesized using a Roche PCR DIG Probe Synthesis Kit (Roche, Penzberg, Germany) with primers CMY-2-RT-F and CMY-2-RT-R (see Table S1 ) and purified using a Millipore Amicon w Ultra Ultracel w 50K filter (Millipore, Billerica, MA, USA). Hybridization was carried out with a Roche DIG Nucleic Acid
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Detection Kit according to the manufacturer's recommendations. The probe demonstrated no cross-reactivity when blotted against 1×10 10 copies of E. coli chromosomal ampC (data not shown).
IncI1 replicon type identification
The plasmid identified as encoding bla CMY-2 by Southern hybridization was extracted from an agarose gel and its DNA was recovered with a QIAGEN QIAquick w Gel Extraction Kit. The extracted plasmid DNA was used as a template for PCRs with the IncI1-specific primers IncI1-F and IncI1-R listed in Table S1 .
RNA folding predictions
Predictions of Inc RNA folding were made using RNAfold WebServer (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi). 31 
Gel mobility shift assays
Gel mobility shift assays were performed for all strains using six doublestranded oligonucleotides of 34-44 bp (see Table S1 ) that represented sequences at 111 and 115 bp upstream of the putative 235 sites of the two CUMC-50 bla CMY-2 transcription start sites located within the insertion element ISEcp1 (GenBank accession number JF300163). Oligonucleotides were synthesized and polyacrylamide-gel-purified by Integrated DNA Technologies (Coralville, IA, USA). Lysate from each strain was obtained from 125 mL of log-phase MHB culture. Cells were washed 3 times with PBS, resuspended in 1.5 mL of sonication lysis buffer (10 mM Tris-HCl, pH 8.0/20% glycerol) and ruptured by sonication using a Gallenkamp Soniprep 150 (MSE, London, UK). Protein concentration of the lysate was measured using a Bio-Rad Quick Start TM Bradford Protein Assay Kit. Oligonucleotides were labelled with [g- 
Results

Piperacillin/tazobactam mutant selection and susceptibilities
Strain CUMC-50 was subjected to superinhibitory concentrations of piperacillin/tazobactam in agar suspension in an attempt to attain mutants with at least a 4-fold higher piperacillin/ tazobactam MIC. Putative mutants were selected at 1×10
26 -1×10 27 cfu. Piperacillin/tazobactam MICs for 18 putative mutants were evaluated, and all were found to have at least an 8-fold increase in MIC compared with CUMC-50.
Strains CUMC-50M, CUMC-50M2 and CUMC-50M8 had piperacillin/tazobactam MICs of 512, 64 and 256 mg/L, respectively, and were retained for further study. Susceptibilities were evaluated for six other b-lactam drugs, and the three mutants were found to have reduced susceptibility to most of the drugs tested compared with the parent strain (Table 1) . Notably, the aztreonam MICs were at a 'susceptible' level (2 mg/L) for the parent, but were 16-to 32-fold higher for the mutants, and considered resistant according to 2011 CLSI breakpoints. 25 All strains were resistant to ceftazidime and susceptible to cefepime and carbapenems.
bla CMY-2 transcript levels
An increase in CMY-2 production due to an increase in bla CMY-2 transcription could have contributed to the elevated b-lactam MICs observed for the mutant strains. When bla CMY-2 transcript levels were evaluated for all strains, the mutants exhibited 3-to 13-fold increases in bla CMY-2 expression (Table 1 ). Higher levels of bla CMY-2 expression correlated with higher b-lactam MICs. No differences in chromosomal ampC expression were observed between parent and mutant strains (data not shown).
bla CMY-2 promoter and structural gene evaluation
The increase in bla CMY-2 gene expression measured in the mutant strains could have been due to bla CMY-2 promoter mutations selected by piperacillin/tazobactam exposure. To evaluate this possibility, 1138 bp of the DNA sequence upstream of the bla CMY-2 gene was examined for each strain. All strains were found to have identical sequences for this region, indicating that no promoter mutations had occurred. Since it was possible inc mutations and increased bla CMY-2 expression that the transcription start site(s) for bla CMY-2 could have been modified even without promoter sequence changes, 5 ′ RACE was used to map the bla CMY-2 transcription start sites for CUMC-50 and CUMC-50M. Both strains were found to utilize two identical start sites located within an ISEcp1 insertion element, at 182 and 624 bp upstream of the bla CMY-2 start codon (GenBank accession number JF300163). These data indicated that there were no changes in promoter sequence or transcriptional start sites affecting mRNA expression. In addition, there were no mutations observed in the bla CMY-2 structural gene among the strains, signifying that the differences in b-lactam susceptibility between CUMC-50 and its mutants were not due to changes in the hydrolytic properties of CMY-2.
Evaluation of transcription factor binding using gel mobility shift assays
Modifications to transcription factors that bind DNA near the bla CMY-2 promoter regions could affect the level of expression. To evaluate this possibility, the regions were evaluated with gel mobility shift assays. No differences in the gel shift patterns of the parent and mutant strains were observed (data not shown), indicating that there were no changes in protein binding to the promoter regions. Taken together, these data suggested that the differences in bla CMY-2 expression observed between parent and mutant strains could not be explained by modifications occurring at the promoter regions, suggesting that another mechanism was responsible.
Evaluation of bla CMY-2 gene copy number
An increase in bla CMY-2 gene copy number could explain the increase in bla CMY-2 expression observed for the mutant strains. When measured by real-time PCR, mutants were found to have 3-to 13-fold increases in bla CMY-2 gene copy number. This directly correlated with the observed increases in bla CMY-2 gene expression (Table 1) .
Two mechanisms could have been responsible for the increases in bla CMY-2 copy number: transposition events may have increased the copy number of bla CMY-2 ; or an increase in the plasmid copy number may have occurred for the plasmid carrying bla CMY-2 . To determine which of these two mechanisms was responsible, a series of Southern blot analyses was performed.
To evaluate plasmid copy-number changes, plasmids were isolated from each strain and analysed by Southern hybridization using a bla CMY-2 -specific probe. In both the parent and mutant strains, bla CMY-2 was found to be located on a single 100 kb plasmid. Among the mutants, the staining intensity of the plasmid band in agarose gels and subsequent Southern blots correlated with the differences observed in bla CMY-2 copy-number assays ( Figure 1a and Table 1 ). 
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To evaluate possible transposition of bla CMY-2 to the chromosome, total genomic DNA from each strain was digested with XbaI then separated by PFGE and analysed by Southern blot analysis. Only the band corresponding to the 100 kb plasmid hybridized with the bla CMY-2 probe in these studies (Figure 1b) , indicating that the CMY-2 gene had not transposed to the chromosome. Again, the intensities of probe-binding reflected the differences in bla CMY-2 copy number for each strain. To rule out possible transposition of bla CMY-2 to other locations on the 100 kb plasmid, total DNA was digested with the more frequently cutting EcoRI endonuclease, then separated by unidirectional gel electrophoresis and analysed by Southern hybridization. In these studies the bla CMY-2 probe hybridized to only a single band of approximately 5700 bp for all strains, and again probe-binding intensity reflected copy-number differences (data not shown).
These Southern blot analyses indicated that plasmid copynumber amplification alone was responsible for the increase in bla CMY-2 copy number of the mutants. To verify this, the 100 kb plasmid carrying bla CMY-2 was excised from an agarose gel and identified as an IncI1 incompatibility-type plasmid through PCR and DNA sequence evaluation. Real-time PCR assays using primers directed at the Incl1 replicon region determined that relative IncI1 plasmid copy number of the mutant strains had also increased between 3-and 13-fold, correlating with the increases in bla CMY-2 copy numbers and bla CMY-2 expression levels that were observed (Table 1) .
inc point mutations and RepZ expression
To determine whether nucleotide changes within inc or its promoter region had occurred in the CUMC-50 mutants, the DNA sequences of inc and its flanking regions were analysed. No changes were observed for CUMC-50 and CUMC-50M2 when compared with the published sequence (e.g. GenBank accession number CP001121.1) (Figure 2 ). However, for strains CUMC-50M and CUMC-50M8, point mutations were present within the loop region of inc. Using the 5 ′ -most transcriptional start site for inc as a reference, 19 an A to G transition at nucleotide 38 and a G to T transversion at nucleotide 30 were observed for strains CUMC-50M and CUMC-50M8 respectively (Figure 2 ). When analysed by RNA folding prediction software, the mutations were found to modify the predicted Inc antisense RNA stem loop structure (Figure 3) , and thus could affect the formation of the kissing complex between Inc and SL1, resulting in the observed increase in plasmid copy number.
Since a mutation that increases repZ transcription could also potentially offset interference by Inc and increase plasmid copy number, relative repZ gene transcript levels were measured, and the repZ promoter regions 12 were sequenced for all strains. No differences in promoter sequence were observed, and the repZ transcript levels of the mutants were increased 3-to 13-fold, matching the levels observed for bla CMY-2 (Table 1) . These data indicated that repZ transcription levels were a reflection of plasmid copy number and most likely not involved in plasmid amplification. 
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Discussion
The present study offers insight into a mechanism by which piperacillin/tazobactam resistance can emerge when an E. coli strain harbours bla CMY-2 on an IncI1 plasmid. In this study, three mutant strains selected by piperacillin/tazobactam exposure from a clinical strain of E. coli possessing bla CMY-2 on a 100 kb IncI1 plasmid were evaluated. Increased bla CMY-2 expression in the mutant strains directly correlated with IncI1 plasmid copy number, and the two mutants with the largest increases in copy number possessed mutations in the inc antisense RNA gene necessary for IncI1 plasmid copy-number control. Mutant strain CUMC-50M8, which exhibited an 8-fold increase in IncI1 plasmid copy number, had a G to T transversion at inc nucleotide 30. This same mutation was evaluated in a previous study by Asano and Mizobuchi, 15 where it was predicted to have a similar effect on stem loop shape, and was associated with a 9-fold increase in plasmid copy number for a ColIB-P9 (IncI1) mini-plasmid construct. Therefore, the mutations found in both the mini-plasmid model system and the 100 kb plasmid evaluated in this study are in agreement and correlate with similar increases in plasmid copy number. To our knowledge this is the first time mutations in inc have been associated with increased copy number of an IncI1 plasmid of this size. Mutant strain CUMC-50M possessed a G to T transition at inc nucleotide 38 and had a 13-fold increase in plasmid copy number. This mutation has not previously been evaluated for its effect on incI1 copy number; however, Asano and Mizobuchi 15 did find this mutation increased the dissociation of Inc and SL1 nucleotides 3-fold and concluded that the nucleotide location was important for formation of the kissing complex. Taken together, these data suggest that the mutation identified in the loop portion of CUMC-50M would affect plasmid copy number. Strain CUMC-50M2 had a 3-fold higher IncI1 plasmid copy number, but demonstrated no changes in inc sequence. Therefore, the increase in plasmid copy number in this strain cannot be explained through this mechanism.
It is unknown if plasmid copy-number mutations like those seen in this study are occurring clinically and contributing to the incidence of piperacillin/tazobactam-resistant E. coli isolated after therapy. However, it is plausible that such mutations are being selected in vivo. In the current study the parent isolate was susceptible to piperacillin/tazobactam (MIC 4 mg/L), and in a clinical setting susceptibility to piperacillin/tazobactam would suggest the drug is a viable treatment option. Subsequent treatment with piperacillin/tazobactam could select for mutations like those seen in this study. The data in this report underscore the need for molecular methodologies in the clinical laboratory to detect plasmid-encoded AmpC b-lactamase genes and provide additional information for the selection of the most appropriate therapy.
IncI1 plasmid copy-number mutations selected by antibiotic pressure can have implications beyond the AmpC b-lactamases. Plasmids of the IncI1 incompatibility type serve as hosts for several other types of b-lactamase genes (e.g. bla CTX-M-14 , bla CTX -M-15 and bla VIM-1 ), as well as resistance genes for other antibiotic classes, such as aminoglycosides (armA and rmtB), macrolides [mph(A)] and quinolones (qnrA1). 4 Mutations that amplify IncI1 copy number could lead to increased expression of these other IncI1-encoded resistance genes. Further studies regarding plasmid architecture are needed to determine the impact plasmid copy-number mutations have on antibiotic susceptibility profiles of organisms that carry plasmid-encoded resistance genes.
